Stocktoria
Spectral AI, Inc. MDAI
Spectral AI, Inc. (MDAI) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $19.6M at a -38.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.3 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.055 |
| Retained earnings / assets | -2.607 |
| EBIT / assets | -0.402 |
| Equity / liabilities | -0.211 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MDAI | Spectral AI, Inc. | 3/9 | -11.78 | — | -33.6% |
| SNOA | Sonoma Pharmaceuticals, Inc. | 2/9 | — | — | +36.7% |
| NEPH | NEPHROS INC | 6/9 | — | 32.8 | +32.7% |
| VVOS | Vivos Therapeutics, Inc. | 2/9 | — | — | +16% |
| DRIO | DarioHealth Corp. | 3/9 | -12.4 | — | -17.3% |
| BDMD | Baird Medical Investment Holdings Ltd | 1/9 | 0.49 | — | -39.2% |
| PROF | Profound Medical Corp. | 5/9 | -3.44 | — | +50.7% |
About Spectral AI, Inc.
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation and delivers a binary prediction on the wounds capacity to heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient's wounds. Its system also develops AI-Burn software and MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images. Spectral AI, Inc. is headquartered in Dallas, Texas.
FAQ
Is MDAI financially healthy?
Spectral AI, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does MDAI pay a dividend?
No, Spectral AI, Inc. does not currently pay a dividend.
How profitable is MDAI?
In FY2025, Spectral AI, Inc. had a net margin of -38.5%.
What is the analyst price target for MDAI?
The average Wall-Street price target for Spectral AI, Inc. is $5.42, about 245.0% above the recent price, from 3 analysts.
Is MDAI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Spectral AI, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.